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Introduction
Platelets are small anucleate cell fragments that have a char-
acteristic discoid shape and range from 1 to 3 µm in diameter. 
Historically, platelets were referred to as cellular dust. We now 
know that they are indispensable for processes such as hemo-
stasis, wound healing, angiogenesis, inflammation, and innate 
immunity. Platelets are formed from the cytoplasm of mega-
karyocytes (MKs), their precursor cells, which reside in the 
bone marrow (Pease, 1956). MKs are the largest (50–100 µm) 
and also one of the rarest cells in the bone marrow; MKs ac-
count for 0.01% of nucleated bone marrow cells (Nakeff and 
Maat, 1974). To assemble and release platelets, MKs become 
polyploid by endomitosis (DNA replication without cell divi-
sion) and then undergo a maturation process in which the bulk 
of their cytoplasm is packaged into multiple long processes 
called proplatelets, and the nucleus is extruded. An MK may 
extend 10–20 proplatelets, each of which starts as a blunt pro-
trusion that over time elongates, thins, and branches repeatedly. 
Platelets form selectively at the tips of proplatelets (Richardson 
et al., 2005). As platelets develop, they receive their granule and 
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organelle content as streams of individual particles transported 
from the MK cell body (Italiano et al., 1999). Platelet formation 
can be arbitrarily divided into two phases: The first phase of 
MK maturation and development takes days to complete and 
requires MK-specific growth factors. During this time, massive 
nuclear  proliferation  and  enlargement  of  the  MK  cytoplasm   
occur as the MK is filled with cytoskeletal proteins, platelet- 
specific granules, and sufficient membrane to complete the 
platelet assembly process. The second phase is relatively rapid 
and can be completed within hours. During this phase, MKs 
generate platelets by remodeling their cytoplasm first into pro-
platelets and then into preplatelets, which undergo subsequent 
fission events to generate discoid platelets. The time required 
for MKs to complete polyploidization, mature, and release 
platelets is 5 d in humans and 2–3 d in rodents (Ebbe and 
Stohlman, 1965; Odell and Jackson, 1968; Odell et al., 1970). 
Once released into the bloodstream, human platelets survive 
7–10 d, whereas rodent platelets survive 4–5 d (Aster, 1967; 
Harker and Finch, 1969; Jackson and Edwards, 1977).
In this review, we outline the process of platelet produc-
tion—starting with MK development and ending with terminal 
platelet formation (illustrated in Fig. 1). After a brief history 
and context of each step, we highlight some exciting recent 
findings and important unanswered questions pertinent to the 
cell biology of platelet formation.
MK maturation and development
MKs develop from hematopoietic stem cells (HSCs) that reside 
mainly in the bone marrow but are also present in the yolk sac, 
fetal liver, and spleen during early development (Long et al., 
1982; Gordon et al., 1990; Ogawa, 1993; Morita et al., 2011). 
During maturation, MKs increase in size, become full of platelet-
specific granules, expand their cytoplasmic content of cyto-
skeletal proteins, and develop a highly tortuous invaginated 
membrane system (IMS; Behnke, 1968; Fig. 2).
Thrombopoietin  (TPO)  directs  MK  develop-
ment. The discovery of TPO, and its MK-specific receptor   
c-Mpl, revolutionized the field of MK and platelet biology. 
Circulating blood platelets are specialized cells that pre-
vent bleeding and minimize blood vessel injury. Large 
progenitor cells in the bone marrow called megakaryo-
cytes (MKs) are the source of platelets. MKs release plate-
lets through a series of fascinating cell biological events. 
During maturation, they become polyploid and accumu-
late massive amounts of protein and membrane. Then, in 
a cytoskeletal-driven process, they extend long branching 
processes, designated proplatelets, into sinusoidal blood 
vessels where they undergo fission to release platelets. 
Given the need for platelets in many pathological situa-
tions, understanding how this process occurs is an active 
area of research with important clinical applications.
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platelet production and allowed study of the mechanisms that 
regulate these processes (Choi et al., 1995; Cramer et al., 1997; 
Lecine et al., 1998). Interestingly, although TPO is one key driver 
of MK differentiation, mice lacking either c-Mpl or TPO suc-
cessfully produce platelets, indicating a role for other regulators 
in the process of proplatelet and platelet formation (Choi et al., 
1995; Ito et al., 1996).
TPO functions as the major regulator that promotes the growth and 
development of MKs from their HSC precursors (Bartley et al., 
1994; de Sauvage et al., 1994; Kaushansky, 1994; Kaushansky 
et al., 1994; Kuter et al., 1994; Lok et al., 1994; Sohma et al., 
1994; Wendling et al., 1994). Subsequently, this discovery facil-
itated development of in vitro cell culture systems that reconsti-
tute MK differentiation, maturation, proplatelet extension, and 
Figure 1.  Schematic of platelet production. (1) HSCs in the bone marrow differentiate into MKs in a TPO-dependent manner. (2) MKs undergo endomitosis 
and develop nuclei ranging in DNA content from 2n to 128n. (3) As MKs mature, they develop a highly invaginated membrane throughout their cytoplasm, 
which is continuous with the external plasma membrane. This membrane serves as a reservoir for proplatelet formation. (4) MKs migrate to the vascular niche, 
where they extend proplatelets and release them into vascular sinusoids. The entire MK is converted into pre/proplatelets, and its nucleus is exuded and phago-
cytosed. (5) Once in the bloodstream, proplatelets interconvert into preplatelets. (6) A fission event creates two platelets from a barbell proplatelet.787 Megakaryocyte development and platelet formation • Machlus and Italiano
of the cleavage furrow, a contractile ring consisting of myosin II 
and F-actin that generates the mechanical forces necessary for 
cell separation (Geddis et al., 2007; Lordier et al., 2008). Spe-
cifically, down-regulation of nonmuscle MYH10 (myosin IIB 
heavy chain) in the contractile ring by RUNX1 (runt-related 
transcription factor 1) is required for the switch from mitosis 
(2n) to endomitosis (4n; Lordier et al., 2012). The importance 
of cleavage furrow inhibition in polyploidization was further 
underscored by examining the mechanism by which it forms. 
RhoA, a small GTPase that regulates the actin cytoskeleton, is 
required to generate the contraction force necessary to complete 
cytokinesis (Melendez et al., 2011). The microtubule-associated 
GEF-H1  activates  RhoA  at  the  cleavage  furrow  (Birkenfeld   
et al., 2007), whereas ECT2 (epithelial cell–transforming se-
quence 2) is involved in RhoA localization and activation 
(Petronczki et al., 2007). Gao et al. (2012) recently revealed 
that both GEF-H1 and ECT2 are down-regulated at the mRNA 
and protein levels during MK polyploidization. Interestingly, 
GEF-H1 down-regulation is required for 2n cells to become 4n, 
Endomitosis.  Endomitosis  (Fig.  1,  step  2)  is  a  pri-
marily TPO-driven process by which MKs become polyploid 
through cycles of DNA replication without cell division (cyto-
kinesis; Ebbe, 1976; Gurney et al., 1994). The study of endo-
mitosis was largely facilitated by the implementation of in vitro 
culture systems that used TPO. During their life cycle, MKs 
first undergo a proliferative 2n stage in which their progres-
sion through the cell cycle is identical to other hematopoietic 
cells. Subsequently, MKs begin endomitosis and accumulate a 
DNA content of 4n, 8n, 16n, 32n, 64n, and even 128n in a single 
polylobulated nucleus before proceeding with their final matu-
ration and proplatelet formation (Zimmet and Ravid, 2000). 
Studies in megakaryocytic-transformed cell lines showed that 
the switch to polyploidization is related to the cell cycle and 
dependent on degradation of cyclin B and reduced activity of the 
cyclin B–dependent Cdc2 kinase (Datta et al., 1996; García and 
Calés, 1996; Zhang et al., 1996, 1998). Subsequent studies with 
primary MKs revealed that endomitosis occurs because of a 
defect in late cytokinesis that results in incomplete formation 
Figure 2.  Transmission electron micrographs of murine MKs, preplatelets, proplatelets, and platelets. MK cultures generated from murine fetal liver cells were 
fixed with 1.25% paraformaldehyde, 0.03% picric acid, and 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, for 1 h, postfixed with 1% osmium te-
troxide, dehydrated through a series of alcohols, infiltrated with propylene oxide, and embedded in epoxy resin. Ultrathin sections were stained and examined 
with an electron microscope (Tecnai G2 Spirit BioTWIN; FEI Company) at an accelerating voltage of 80 kV. Images were recorded with a charge-coupled de-
vice camera (2K; Advanced Microscopy Techniques) using digital acquisition and analysis software. (A) Overview of one MK showing multilobulated nucleus 
and IMS. (B) MK with a highly developed IMS. (C) Released preplatelets (#), proplatelets (*), and platelets (^). (D) Detailed view of platelets (bottom right) and 
an MK, highlighting its contents. N, nucleus; IMS, invaginated membrane system; G, granule; M, mitochondria; V, multivesicular body.JCB • VOLUME 201 • NUMBER 6 • 2013   788
et al., 2012). Although nicotinamide does increase ploidy, its 
effect on platelet formation is controversial. Some observed 
nicotinamide-induced increased proplatelet production in vitro 
(Giammona et al., 2006), whereas others saw reduced proplatelet 
formation (Giammona et al., 2006; Leysi-Derilou et al., 2012). 
Importantly, administration of nicotinamide to mice does not in-
crease their platelet levels (Konieczna et al., 2013). In addition, 
overexpression of cell cycle regulators, such as cyclin D3, has 
been shown to enhance MK ploidy in vivo without any concomi-
tant increase in platelet count (Zimmet et al., 1997). As we learn 
more about the process of endomitosis and how to manipulate it, 
we will be better able to reveal whether high nuclear content is 
causative or correlative to platelet formation.
The IMS: A membrane reservoir. One purpose of 
endomitosis is to generate the large quantity of protein and lipid 
synthesis necessary to create the IMS (previously referred to   
as the demarcation membrane system). The IMS (Fig. 1, step 3)   
is an extensive complex of cisternae and tubules distributed 
throughout the MK cytoplasm that is continuous with the plasma 
membrane and is thought to exist as a membrane reservoir for 
proplatelet formation (Yamada, 1957; Radley and Haller, 1982). 
Schulze et al. (2006) confirmed this hypothesis by demonstrating 
that the IMS is indeed the origin of the proplatelet and platelet 
surface. Furthermore, the force necessary for internal IMS mi-
gration relies on actin filament assembly via the WASP–WAVE 
whereas ECT2 down-regulation is required for polyploidization 
beyond 4n. This suggests that different mechanisms may be reg-
ulating the initial 2n to 4n transition versus subsequent endomi-
totic events (Papadantonakis et al., 2008; Gao et al., 2012).
These studies do not, however, preclude a role for the cell 
cycle in endomitosis. Although inhibition of cleavage furrow for-
mation physically prevents the MK from dividing, there still may 
be a separate process that regulates the repeated cycles of DNA 
replication. Multiple studies have identified roles for G1/S-phase 
regulators, such as the cyclins D and E, supporting the hypothesis 
that up-regulation of G1-phase components may be important in 
promoting cycles of endomitotic DNA synthesis to allow for the 
development of high ploidy MKs (Zimmet et al., 1997; Muntean 
et al., 2007; Eliades et al., 2010).
It is theorized that MKs are polyploid to produce the large 
quantities of mRNA and protein necessary to be packaged into 
platelets while still retaining their ability to perform multiple 
functions without the stress of mitosis and cytokinesis (Zimmet 
and Ravid, 2000). Although endomitosis and polyploidization 
are undoubtedly important for MK cytoplasmic maturation, the 
relationship between high nuclear DNA content and efficient 
platelet formation is still highly debated. For example, nicotin-
amide, a form of vitamin B3, is commonly used to increase the 
ploidy of human and mouse MKs in culture (Giammona et al., 
2006; Panuganti et al., 2010; Avanzi et al., 2012; Leysi-Derilou 
Figure 3.  Microtubules in proplatelets and platelets. Microtubules composed of 1-tubulin line the shafts of proplatelet extensions and form a microtubule 
coil in nascent platelet tips and released preplatelets/platelets. To delineate the microtubule cytoskeleton, murine fetal liver MK-generated samples were 
incubated with a rabbit polyclonal primary antibody for 1-tubulin, washed, and probed with a secondary Alexa Fluor 488 nm–conjugated antibody. 
MKs were imaged on a microscope (Eclipse TE2000-E; Nikon) equipped with a 63× objective, NA 1.4, and 1.5× optivar. Images were acquired with   
a charge-coupled device camera (ORCA-II-ER; Hamamatsu Photonics). Image acquisition was under the control of MetaMorph software (Molecular Devices). 
(A–C) Images highlight the branching of proplatelets (A), heterogeneous mix of platelets, pre- and proplatelets released from MKs (B), and the figure 8   
structure seen in preplatelet to proplatelet interconversion (C).789 Megakaryocyte development and platelet formation • Machlus and Italiano
these data, mutations in the MYH9 gene that reduce myosin II 
activity have been implicated in the May-Hegglin anomaly and 
related macrothrombocytopenias (Kelley et al., 2000; Seri et al., 
2000). More recently, MYH9 mutations have been associated 
with premature initiation of proplatelet formation within the 
bone marrow. This is mediated by disruption in the Rho–Rho 
kinase–myosin-IIA pathway and leads to decreased numbers 
of circulating platelets (Chang et al., 2007; Chen et al., 2007). 
These observations are supported by mouse models showing 
that mutations in the MYH9 gene cause both cultured MKs and 
those in the bone marrow to produce fewer and shorter proplate-
lets with less branching (Zhang et al., 2012b). Recently, Bluteau 
et al. (2012) further highlighted the importance of myosin regu-
lation by showing that RUNX1 can affect proplatelet formation 
by direct regulation of MYL9, MYH10, and MYH9. This study 
may explain one reason why patients with familial platelet dis-
order with predisposition to acute myelogenous leukemia, a fa-
milial platelet disorder characterized by germline heterozygous 
RUNX1 alterations, present with thrombocytopenia.
Although these studies suggest that regulation of the cy-
toskeleton is necessary for efficient proplatelet formation, their 
focus is largely on deficiencies or mutations that diminish pro-
platelet formation. In the future, it will be important to investigate 
whether direct manipulation of the cytoskeleton can augment or 
even initiate the process of proplatelet formation directly.
The  cytoskeleton  highway  connects  the  MK 
body to budding platelets. In addition to playing an essen-
tial role in proplatelet elongation, microtubules lining the shafts of   
proplatelets serve a second function: transportation of organelles 
and granules into proplatelets and assembly of platelets at pro-
platelet ends. In MKs, granules are derived from budding of small 
vesicles containing granule cargo from the trans-Golgi network 
(Blair and Flaumenhaft, 2009). Vesicles budding from the trans-
Golgi network may be delivered directly to multivesicular bodies, 
where proteins are sorted and eventually packaged into granules 
(Heijnen et al., 1998; Youssefian and Cramer, 2000). Organelles 
and granules are then sent individually from the MK cell body into 
the proplatelets, where they move bidirectionally until they are 
captured at proplatelet tips (Fig. 4; Richardson et al., 2005). Inter-
estingly, this process bears striking resemblance to neuronal cells 
in which axons can reach millimeters in length and also need to 
transport organelles long distances. In MKs, immunofluorescence 
and electron microscopic experiments indicate that organelles are 
intimately associated with microtubules, and actin drugs do not 
affect organelle motion (Richardson et al., 2005). Thus, move-
ment appears to be microtubule based (Richardson et al., 2005). 
The bipolar arrangement of microtubules within the proplatelet 
contributes to bidirectional organelle movement. The plus end– 
directed microtubule motor kinesin localizes in a pattern similar 
to organelles and granules, implicating this motor in transport of 
organelles along microtubules. There appears to be two aspects 
of this process: first, organelles and granules travel along micro-
tubules, and second, the microtubules themselves slide bidirec-
tionally in relation to other motile filaments, indirectly moving 
organelles along proplatelets (Richardson et al., 2005). Although 
microtubule highways appear to transport granules and organ-
elles long distances along proplatelets, the mechanism by which 
pathway at the IMS cytoplasmic face in response to phosphati-
dylinositol 4,5-bisphosphate signaling (Schulze et al., 2006).
Not surprisingly, the IMS also requires cytoskeletal sup-
port. Spectrin, a protein that forms the plasma membrane skeleton 
in many cell types, forms a 2D lattice in MKs that underlies and 
stabilizes the IMS; MKs expressing a dominant-negative spectrin 
peptide have an underdeveloped IMS with insufficient membrane 
to form proplatelets (Patel-Hett et al., 2011). Thus, a developed 
and mature IMS aided by the spectrin membrane skeleton helps 
establish and maintain proplatelets during platelet biogenesis 
(Patel-Hett et al., 2011). Although evidence suggests that the IMS 
functions as a membrane reservoir for proplatelet elongation, there 
are still several questions that need to be addressed. For example, 
IMS continuity with the plasma membrane in mature MKs may 
suggest that plasma membrane invagination is involved in IMS 
formation. In addition, other internal pools of membrane, such as 
the endoplasmic reticulum or Golgi, may contribute to IMS devel-
opment and/or initiate this process.
Terminal MK development and  
proplatelet formation
Mature MKs extend long branching processes called proplatelets 
into the sinusoidal blood vessels of the bone marrow. Proplate-
lets, which function as the assembly lines of platelet production, 
are comprised of platelet-sized swellings in tandem arrays that 
are connected by thin cytoplasmic bridges (Fig. 1, step 4; Italiano 
et al., 1999). Proplatelet production has been observed in vivo by 
imaging proplatelets extending into the sinusoidal blood vessels 
of bone marrow (Behnke, 1969; Becker and De Bruyn, 1976; 
Junt et al., 2007; Zhang et al., 2012a). Spontaneous proplatelet 
formation also occurs in vitro with MKs derived from murine   
fetal liver stem cells (Italiano et al., 1999; Patel et al., 2005a; Thon 
et al., 2010, 2012a) and human cell–derived MKs (Choi et al., 
1995; Miyazaki et al., 2000; Chang et al., 2007; Dunois-Lardé 
et al., 2009). Currently, we have an insufficient understanding of 
the signals that trigger proplatelet formation in MKs, resulting in a 
significant gap in our knowledge of platelet production.
The  cytoskeleton  powers  proplatelet  exten-
sion. Accumulating evidence suggests that the cytoskeleton is 
the principal machinery for platelet production (Tablin et al., 
1990; Hartwig and Italiano, 2006; Thon et al., 2010). This is not 
unexpected, considering the massive reorganization a mature, 
round MK goes through to extend proplatelets and release them 
into sinusoidal blood vessels. 1-Tubulin is the main tubulin 
isoform in MKs; its reorganization is essential for proplatelet 
formation and powers proplatelet elongation using cytoplas-
mic dynein, a microtubule minus end–associated motor protein 
(Fig. 3; Lecine et al., 2000; Patel et al., 2005b). Mice lacking 
1-tubulin produce 60% fewer platelets, and the platelets that 
are produced show structural and functional defects, including 
reduced microtubule content and fewer microtubule coilings 
around the platelet periphery (Schwer et al., 2001). In humans, 
mutations in 1-tubulin result in an autosomal dominant macro-
thrombocytopenia (Kunishima et al., 2009).
Likewise, F-actin is present throughout proplatelets and 
forms the assembly points required for them to bend and bifur-
cate (Italiano et al., 1999; Patel et al., 2005b). Consistent with JCB • VOLUME 201 • NUMBER 6 • 2013   790
is not required for platelet production. Nevertheless, the effi-
ciency of platelet production in culture is decreased relative to 
that observed in vivo, suggesting that the bone marrow micro-
environment plays an important role in stimulating and enhanc-
ing proplatelet formation and platelet release.
The osteoblastic niche. It has been hypothesized that 
the dynamic interaction of MKs with the different extracellular 
matrix proteins in the bone marrow compartmentalizes their 
maturation to specific sites. This is important to allow MKs to 
first develop from HSCs and then migrate to the vascular niche 
before beginning the process of proplatelet formation. Colla-
gen I is the most abundant component of the osteoblastic niche 
(Reddi et al., 1977). Interestingly, binding of MKs to collagen 
through 21-integrin inhibits proplatelet formation (Sabri   
et al., 2004, 2006; Zou et al., 2009). This suggests that under nor-
mal physiological conditions, the osteoblastic niche inhibits pro-
platelet formation (Arai and Suda, 2007; Pallotta et al., 2009). 
Recently, an in vitro model to study MK function in the bone 
marrow environment was developed by differentiating human 
mesenchymal stem cells into osteoblasts and then co-culturing 
osteoblasts with HSCs and MKs (Pallotta et al., 2009). Using 
this model, Pallotta et al. (2009) found that HSCs form a niche 
that leads to collagen I deposition, creating an environment con-
ducive for HSCs to differentiate through the megakaryocytic 
lineage but not to complete maturation and extend proplatelets. 
This supports the model that engagement of collagen I in the 
osteoblastic niche acts to suppress proplatelet formation while 
allowing for MK differentiation and maturation.
The vascular niche. Polyploid MKs localize to sinu-
soidal bone marrow endothelial cells in vivo, where they form 
proplatelets that migrate through bone marrow endothelial cells, 
and release platelets directly into the marrow intravascular 
sinusoidal space (Tavassoli and Aoki, 1989). Recent evidence 
suggests that up-regulation of the cytokine SDF-1 and its re-
ceptor CXCR4 may be important for the migration of MKs to 
the vascular niche (Avecilla et al., 2004; Pitchford et al., 2012). 
The vascular niche is comprised of extracellular matrix proteins, 
such as collagen IV, fibronectin, fibrinogen, and von Willebrand 
factor, which in conjunction with chemokine-mediated interac-
tion of progenitors allow MKs to relocate to a microenvironment 
that is both permissive and instructive for the late stages of MK 
maturation and proplatelet formation (Avecilla et al., 2004).
Fibrinogen is a commonly studied extracellular matrix pro-
tein in bone marrow sinusoids that enhances proplatelet forma-
tion. MKs from bone marrow aspirates form significantly more 
proplatelets when plated on fibrinogen (Larson and Watson, 
2006). The mechanism for this augmentation is thought to be 
through fibrinogen binding to the MK integrin IIb3 (Eto et al., 
2002; Larson and Watson, 2006). Although IIb is expressed in 
MK progenitor cells, and thus very early in MK development, its 
role throughout MK maturation remains controversial (Berridge 
et al., 1985; Prandini et al., 1996). A study by Eto et al. (2002) 
suggests that IIb3 only exhibits agonist-induced fibrinogen 
binding in mature MKs. Aside from its role in binding fibrino-
gen, the integrin IIb3 in itself may be important for proplatelet 
release; a study shows that antibodies directed against the in-
tegrin subunit IIb inhibit proplatelet formation when added to 
the necessary organelles and granules are packaged into plate-
lets remains unclear. In addition, the idea that granules may 
be sorted into heterogeneous populations in platelets remains 
controversial (Italiano et al., 2008; Kamykowski et al., 2011; 
Jonnalagadda et al., 2012). Furthermore, recent studies have 
identified heterogeneity in -granule morphology and mem-
brane protein composition as well as granule motility during 
platelet activation (van Nispen tot Pannerden et al., 2010; Peters 
et al., 2012). In the future, studies addressing this question may 
help us better understand the many unique roles platelets and 
their cargo play in health and disease.
The role of the microenvironment  
in proplatelet formation
MKs cultured in vitro can form proplatelets in suspension, sug-
gesting that direct interaction with the bone marrow environment 
Figure 4.  Trafficking of -granules. Granules are packaged in MKs, traf-
ficked along microtubules lining proplatelet (Proplt) shafts, and captured 
in nascent platelet tips. To visualize -granules, murine fetal liver–derived 
MKs were incubated overnight with 150 µg/ml Oregon green 488 human 
fibrinogen conjugate, which they take up and package into their -granules. 
MKs were then washed by albumin gradient sedimentation, and the resus-
pended pellet was placed in a video chamber. MKs were imaged on a 
microscope (Nikon) equipped with a 100× objective, NA 1.4, and were 
acquired with a charge-coupled device camera (ORCA-II-ER). Image acqui-
sition was under the control of MetaMorph software. (A and B) Images visu-
alize MKs actively releasing proplatelets (A) and released proplatelets (B).791 Megakaryocyte development and platelet formation • Machlus and Italiano
proplatelet extension and release. Once in the blood, proplate-
lets are exposed to a high S1P concentration, which initiates the 
subsequent shedding of platelets into the circulation. Using S1pr1 
knockout mice and multiphoton intravital microscopy, they 
showed that the S1P gradient guides proplatelet extensions into 
the lumen of the bone marrow sinusoids and that mice lacking 
S1pr1 develop severe thrombocytopenia caused by both forma-
tion of extravascular proplatelets and defective proplatelet release 
inside the vascular space. Importantly and perhaps most exciting 
is that activation of S1pr1 signaling directly stimulated the release 
of new platelets; this is mediated through S1pr1, which triggers 
activation of the Gi/Rac GTPase signaling cascade. Therefore, 
this study identifies S1P and its receptor S1pr1 as important me-
diators of directional proplatelet elongation and terminal shed-
ding of new platelets into the blood stream. The implications of 
this study are far reaching and open the door to many interesting 
questions. For example, as proplatelets extend into the lumen, 
could they also function to monitor circulating levels of proteins, 
such as TPO, or even platelet numbers? This would allow the 
MK to receive information and instruct the MK in processes such 
as protein translation, granule packaging, and platelet production. 
Understanding the impact of blood components on proplatelet 
formation is an exciting field for future work.
Proplatelet extension into the vascular space. 
Once the lumen is “sensed” by the MK, how are the proplatelets 
able to break through into the vascular space? In another recent 
study, it was revealed that podosomes, cylindrical actin-rich 
structures found on the outer surface of the plasma membrane, 
actively degrade the extracellular matrix and are therefore 
important for MKs to extend proplatelet protrusions across the 
basement membrane (Schachtner et al., 2013). This study showed 
that the mechanism by which MKs form podosomes is through 
actin polymerization via the Arp2/3 complex and WASP to cre-
ate an F-actin core, which is then surrounded by rings of vincu-
lin. Once assembled, podosomes degrade matrix proteins, such 
as fibrinogen, in a matrix metalloproteinase- and myosin-IIA– 
dependent manner. This study is the first to examine the role of 
podosomes in MKs and suggests that they may play a role in 
effective delivery of platelets into the bloodstream during pro-
platelet formation.
Similarly, the impact of blood shear forces on proplatelet 
formation is an emerging trend in the field of MK and plate-
let biology. In a pivotal study, Junt et al. (2007) observed pro-
platelet formation in real time in the bone marrow of mice by 
multiphoton intravital microscopy. Their observations in these 
live-cell experiments uphold the hypothesis that blood flow–
induced shear stress helps separate proplatelet fragments from 
the MK cell body. This was supported by an in vitro model in 
which cultured MKs shed significantly more proplatelets when 
they were agitated compared with MKs in static cultures (Junt 
et al., 2007). In a complementary study, the role of shear on 
platelet release from human cord blood MKs adhered to a von 
Willebrand factor matrix was examined (Dunois-Lardé et al., 
2009). During exposure to high shear rates (1,800 s
1), cyto-
plasmic MKs produced extensions organized along the direc-
tion of flow in a manner dependent on both microtubules and 
the GPIb receptor (Dunois-Lardé et al., 2009). Together, these 
cultured MKs (Takahashi et al., 1999). Interestingly, patients with 
Glanzmann’s thrombasthenia, a disease characterized by either 
absent or nonfunctioning IIb3, still have a normal level of circu-
lating platelets (Caen et al., 1966). Therefore, IIb3 may enhance 
but is not necessary for proplatelet formation.
In contrast, patients with Bernard-Soulier syndrome display 
thrombocytopenia with giant platelets in addition to functional 
defects like defective platelet adhesion to subendothelium and 
reduced platelet aggregation (Ware et al., 1993). Bernard-Soulier 
syndrome is linked to genetic lesions of the platelet membrane 
glycoprotein complex GPIb–IX–V, which contains the binding 
site for von Willebrand factor, a plasma glycoprotein important 
for platelet adhesion to the endothelium (Geddis and Kaushansky, 
2004). Therefore, it appears that GPIb–IX–V may be necessary 
for efficient platelet formation. In fact, in vitro studies have 
shown that antibodies against GPIb–IX–V strongly inhibit pro-
platelet production and that MKs derived from patients with 
Bernard-Soulier syndrome do not extend proplatelets in vitro 
(Takahashi et al., 1999; Balduini et al., 2011). These studies 
suggest that one mechanism by which GPIb–IX–V mutations 
cause macrothrombocytopenia in patients is through defective 
proplatelet formation.
Fibronectin is another abundant protein in the hematopoi-
etic microenvironment and is a proliferative stimulus for HSCs 
(Weinstein et al., 1989; Vuillet-Gaugler et al., 1990). Specifically, 
it plays an important role in megakaryocytopoiesis, proliferation, 
and  differentiation  through  adhesion  to  fibronectin  receptors 
VLA-4 (very late antigen 4) and VLA-5 (Han et al., 2004; Fox 
and Kaushansky, 2005). Recently, the role of these receptors in 
proplatelet formation was examined by Matsunaga et al. (2012), 
who found that fibronectin-activated VLA-4 and VLA-5 may 
contribute to proplatelet formation through enhanced activation 
of ERK1/2. Although preliminary, these data are the first to sug-
gest a mechanism by which fibronectin augments proplatelet 
formation. In sum, these studies suggest a model in which the 
osteoblastic niche provides an environment that allows MKs to 
mature and develop, whereas the vascular niche enhances pro-
platelet formation.
How proplatelets find their way  
into sinusoidal blood vessels
Directed  release  of  proplatelets  by  MKs. In addi-
tion to functioning as the assembly lines for platelet produc-
tion, the architecture and morphology of proplatelets provide 
a mechanism to deliver platelets to the bloodstream. Observa-
tions of MKs releasing proplatelets in vivo have led to the no-
tion that there is directional release of proplatelets from MKs. It 
is only recently, however, that studies have begun to elucidate 
how MKs do this. Although MK receptor engagement of extra-
cellular matrix proteins in the vascular niche is important, an-
other less-studied interaction involves exposure of MKs and/or 
newly generated proplatelet extensions to blood components. 
Because of their unique position at the vascular interface, MKs 
are effectively exposed to a transendothelial gradient of blood 
components. Recently, an elegant study by Zhang et al. (2012a) 
exploited this phenomenon and identified S1P (sphingosine 1 phos-
phate) and its receptor on MKs, S1pr1, as important mediators of   JCB • VOLUME 201 • NUMBER 6 • 2013   792
Platelet size correlates with platelet reactivity; larger plate-
lets have greater prothrombotic potential. Elevated platelet size 
(mean  platelet  volume)  is  associated  with  increased  platelet 
aggregation, increased expression of adhesion molecules, and 
elevated risk of cardiovascular and peripheral arterial diseases 
(Bath and Butterworth, 1996; Kamath et al., 2001; Berger et al., 
2010; Chu et al., 2010; Slavka et al., 2011). Interestingly, a study 
of patients with acute coronary disease found a direct associa-
tion between 2-integrin chain expression and mean platelet vol-
ume, suggesting that expression levels of integrin 21 may be 
involved in the regulation of platelet size (Kunicki et al., 2012). 
Recently, this was supported by the creation of conditional MK-
specific 2-integrin chain (Itga2
/)–deficient mice in which the 
resulting platelets have a significantly decreased mean platelet 
volume (Habart et al., 2013).
These observations begin to explain platelet size under 
normal, physiological conditions and also genetic variations that 
may result in macrothrombocytopenia. However, there is still 
much to be revealed about what regulates platelet size. A recent 
paper addressed this issue in a novel way; Gieger et al. (2011) 
conducted a high-powered meta-analysis of genome-wide asso-
ciation studies in >66,000 individuals. From this genome-wide 
association study, 68 genomic loci associated with platelet vol-
ume were identified, including both previously studied and novel 
regulators of platelet formation. Studies such as this pave the 
way for future research into genes that regulate platelet produc-
tion, the results of which will be integral in understanding what 
molecular pathways regulate both platelet formation and size.
Translating MK cell biology into medicine
Platelets are essential for hemostasis, and thrombocytopenia 
(platelet counts < 150 × 10
9/liter) is a major clinical problem 
encountered across several conditions, including idiopathic 
thrombocytopenic  purpura  (ITP),  myelodysplastic  syndromes, 
chemotherapy, aplastic anemia, human immunodeficiency virus 
infection, complications during pregnancy, and surgery. It is es-
timated that 1.5 million platelet transfusions to prevent severe 
bleeding are administered yearly, with each transfusion costing 
over $600 (Kaushansky, 2008). Therefore, because of the strong 
effect of TPO on platelet production, clinical trials evaluating 
the use of recombinant TPO to treat thrombocytopenia began 
in 1995 (Kuter and Begley, 2002). Unfortunately, some patients 
treated with recombinant TPO developed antibodies that created 
a paradoxical decrease in platelets. This led to the creation 
of TPO mimetics, such as romiplostim and eltrombopag, which 
are highly effective in raising the platelet count in ITP (Li et al., 
2001). Although effective in treatment of ITP and other chronic 
conditions, TPO mimetics take 5 d to increase platelet counts and 
12 d to reach maximum effect, making them less useful in acute 
situations (Kuter, 2010). In addition, one serious side effect of 
current TPO mimetics is development of bone marrow myelo-
fibrosis (Kuter et al., 2009). Therefore, it is obvious that other 
alternatives (in addition to platelet transfusions) are necessary to 
instantaneously elevate platelet counts in situations such as sur-
gery, sepsis, trauma, or disseminated intravascular coagulation.
The ability to make platelets from cultured MKs would 
be an extremely valuable clinical tool. Because of this, several 
results support the idea that intravascular release of fragments 
protruding from mature MKs is aided by fluid shear forces in 
bone marrow sinusoids. However, the majority of these studies 
have been performed using in vitro assays examining platelet 
rolling and adhesion in an open system. The development of 
microfluidic chips that recapitulate the bone marrow and vas-
cular compartments will likely provide new insights into how 
shear influences proplatelet production and release.
Terminal platelet formation and release
Once proplatelets are extended into the blood stream, what hap-
pens? Do small, platelet-sized objects or larger fragments get re-
leased into circulation? In light of recent work, it appears that 
MKs release a heterogeneous mix into the blood, indicating that 
terminal platelet formation may continue in the blood stream. 
The presence of proplatelet-like structures in blood has been 
long recognized, and it is therefore likely that proplatelets rou-
tinely fragment from the MK body, enter the blood, and mature 
into platelets while in circulation. Schwertz et al. (2010) revealed 
that platelets are capable of producing progeny; platelets pro-
duce “figure 8” barbell-shaped structures with two platelet-sized 
bulbs on each end that contain their own organelles and cyto-
skeletal system (illustrated in Fig. 3 C). This duplication occurs 
in vitro over a few hours, is dependent on an intact microtubular 
network, and is associated with increased protein synthesis. Sub-
sequently, Thon et al. (2010) identified a new stage in platelet 
formation present in both cultured MKs and peripheral blood 
smears, the preplatelet. Preplatelets are anucleate discoid parti-
cles that are 2–10 µm in diameter that can reversibly convert into 
barbell-shaped proplatelets (Fig. 1, step 4). As in the study by 
Schwertz et al. (2010), Thon et al. (2012a) found that preplate-
lets are able to mature into platelets both in vitro and after trans-
fusion into mice in vivo. Additionally, it was uncovered that this 
is a microtubule-mediated process; bidirectional polymerization 
of microtubules at each end of the barbell proplatelet forms two 
platelet-sized (2-µm diameter) microtubule coils at each end, 
which split into two individual platelets after an abscission event 
(Fig. 1, step 5; Thon et al., 2010).
Regulation of terminal platelet size. The conver-
sion  from  pre-  to  proplatelet  is  driven  by  microtubule-based 
forces, which are governed by two major biophysical properties: 
microtubule coil diameter and microtubule coil thickness (Thon 
et al., 2012b). Interestingly, these forces both regulate and predict 
the size of circulating platelets generated by proplatelets, provid-
ing an explanation for the 2-µm diameter of platelets (Thon   
et al., 2012b). This supports a model in which circular preplate-
lets are released into the blood, rapidly and spontaneously con-
vert into barbell proplatelets, and undergo fast rounds of abscission 
that result in mature platelets. Alternatively, preplatelets may be-
come trapped in the microcapillaries of the bone marrow, lung, or 
spleen where intravascular shear forces drive proplatelet to 
platelet production. A study of higher platelet counts in postpul-
monary vessels suggests that the lung may be a site of terminal 
platelet formation (Howell and Donahue, 1937). In addition, a 
study using rat models reveals that lung damage may reduce cir-
culating platelets, suggesting that the lungs play an active role in 
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Future perspectives
We have made substantial progress on understanding the mecha-
nisms that regulate thrombopoiesis and platelet formation. But, 
as is often the case in science, new discoveries lead to more 
questions. Interestingly, the field of platelet biology is beginning 
to move away from thinking of platelets as just mediators of he-
mostasis and starting to study their role in other processes such 
as inflammation, immunity, and cancer. Are there humoral regu-
lators of proplatelet production and platelet release? Along with 
these “new” roles for platelets, we have yet to fully uncover what 
signaling pathways initiate and regulate various aspects of 
platelet production, in particular, proplatelet initiation, sliding, 
branching, and release. In addition to revealing fundamental cel-
lular mechanisms, future studies of platelet production will en-
hance our understanding of how pathological processes in the 
body affect platelet production and may lead to improved treat-
ments for thrombocytopenia.
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